World journal of urology · 2025
Clinical study of the postural drainage lithotripsy system for the treatment of residual fragments after retrograde intrarenal surgery.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liangliang Dai, Hanping Wei, Chenjie Qiu, Tingchun Wu, Zhimin Jiao, Xiaoliang Yuan, Tao Yang, Honglei Shi
Аннотация
PURPOSE: The aim of this study was to compare the efficacy of two surgical modalities, Retrograde Intrarenal Ureteral Lithotripsy (RIRS) and PDLS + RIRS (Retrograde Intrarenal Ureteral Lithotripsy Combined with Posterior Drainage Lithotripsy System), in terms of stone removal, and to provide a basis for decision-making in clinical treatment.
METHODS: This prospective study was carried out from 2022-02-16 to 2025-02-16 and included patients attending our hospital to collect clinical data, with surgery performed by the same attending surgeon. Patients with RFs determined by X-ray or CT 1-3 days after RIRS were selected and randomly divided into a treatment group (PDLS intervention) and a control group (conventional instruction). Patients in the treatment group were treated with preoperative water to hold urine and PDLS for 10 min, adverse effects and stone expulsion were recorded, and stone clearance status was determined by mean imaging follow-up for 20 days. The sample size was calculated using PASS 11 software, and 136 samples were identified for participation in the experiment, and the data were analysed using R 4.3.0 statistical analysis software.
RESULTS: There was no statistically significant difference between the two groups in terms of baseline characteristics such as Age, BMI, CT value, Gender, Hypertension, Diabetes, Respiratory disease, History of RIRS surgery, Haematuria, Back pain and Fever (P > 0.05). However, in terms of stone-free rate, the PDLS + RIRS group had a significantly higher stone-free rate (91.67%) than the RIRS group (75.00%), and the difference was statistically significant (χ²=6.94, P = 0.008).
CONCLUSION: Studies have shown that the PDLS + RIRS surgical approach has higher efficiency and advantages in stone removal, which can be used as a reference for clinical treatment.
CLINICAL TRIAL REGISTRY NUMBER: ChiCTR2300071185; Registration date: 2023-05-06.
METHODS: This prospective study was carried out from 2022-02-16 to 2025-02-16 and included patients attending our hospital to collect clinical data, with surgery performed by the same attending surgeon. Patients with RFs determined by X-ray or CT 1-3 days after RIRS were selected and randomly divided into a treatment group (PDLS intervention) and a control group (conventional instruction). Patients in the treatment group were treated with preoperative water to hold urine and PDLS for 10 min, adverse effects and stone expulsion were recorded, and stone clearance status was determined by mean imaging follow-up for 20 days. The sample size was calculated using PASS 11 software, and 136 samples were identified for participation in the experiment, and the data were analysed using R 4.3.0 statistical analysis software.
RESULTS: There was no statistically significant difference between the two groups in terms of baseline characteristics such as Age, BMI, CT value, Gender, Hypertension, Diabetes, Respiratory disease, History of RIRS surgery, Haematuria, Back pain and Fever (P > 0.05). However, in terms of stone-free rate, the PDLS + RIRS group had a significantly higher stone-free rate (91.67%) than the RIRS group (75.00%), and the difference was statistically significant (χ²=6.94, P = 0.008).
CONCLUSION: Studies have shown that the PDLS + RIRS surgical approach has higher efficiency and advantages in stone removal, which can be used as a reference for clinical treatment.
CLINICAL TRIAL REGISTRY NUMBER: ChiCTR2300071185; Registration date: 2023-05-06.